VEGFA and neoplasm: Further studies have investigated the efficacy of natalizumab, an anti-VLA4 mAb used for the treatment of multiple sclerosis that binds α4 integrins, in order to prevent the interaction between ECM components, BM stromal cells, and malignant PCs; it has emerged that the drug slows tumor cell proliferation, VEGF secretion, and angiogenesis and strengthens the effects of bortezomib and dexamethasone [93].